At Least 30 Children Have Died From This Season ’s Flu. Some of Them Were Perfectly Healthy

Thirty children have died from confirmed influenza-related causes so far this flu season, according to the Centers for Disease Control and Prevention’s (CDC’s) most recent weekly report, released last Friday. The total includes deaths between Oct. 16 and Jan. 13. CDC Director Brenda Fitzgerald has described the 2017-2018 flu season as “very active,” and has said that much of the country is experiencing “widespread and intense flu activity.” During a Jan. 12 press update, Fitzgerald said that influenza A, H3N2, has been the most common strain of flu virus reported this year. “These viruses are often linked to more severe illness, especially among children and people age 65 and older,” she said. Most children who get the flu do recover. But thousands are hospitalized every year, and some die from complications. The number of children killed by influenza-related causes per season has ranged over the last decade from a low of 37 (in 2011-2012) to a high of 288 (in 2009-2010). The current flu season is, so far, on track to be deadlier for children than the previous two. During last year’s flu season, 110 children died from the flu between November 2016 and September 2017, with 17 pediatric deaths reported through the second week of January last year. During the 2015-2016 flu season, 92 children died from the flu, with 10 child deaths by this point in the season. But there have also been worse seasons in recent years: Compared ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized healthytime onetime public health Source Type: news

Related Links:

Authors: Rombauts A, Abelenda-Alonso G, Cuervo G, Gudiol C, Carratalà J Abstract INTRODUCTION: Despite adequate antibiotic coverage, community-acquired pneumonia (CAP) remains a leading cause of hospitalization and mortality worldwide. It induces both a local pulmonary and a systemic inflammatory response, particularly significant in severe cases. The intensity of the dysregulated host response varies from patient to patient and has a negative impact on survival and other outcomes. AREAS COVERED: This comprehensive review summarizes the pathophysiological aspects of the inflammatory response in CAP, brie...
Source: Expert Review of Anti-Infective Therapy - Category: Infectious Diseases Tags: Expert Rev Anti Infect Ther Source Type: research
CONCLUSIONS: Xyloglucan/gelose plus ORS was effective and safe in treating acute diarrhea in children. PMID: 33028102 [PubMed - as supplied by publisher]
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research
Authors: Siamashvili M, Davis S Abstract INTRODUCTION: Bromocriptine mesylate quick release (QR) is a dopamine D2 receptor agonist and is the only oral, primarily centrally acting drug that can be used for the treatment of adults with type 2 diabetes. AREAS COVERED: The authors describe current recommendations on the use of bromocriptine mesylate QR. Major efficacy and safety parameters of the late phase trials, including The Cycloset Safety Trial, have been identified and presented. EXPERT OPINION: Efficacy of bromocriptine mesylate QR monotherapy appears to be low but is compensated by favorable safety pr...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Publication date: Available online 9 October 2020Source: Nutrition, Metabolism and Cardiovascular DiseasesAuthor(s): Vanda Craveiro, Elisabete Ramos, Joana Araújo
Source: Nutrition, Metabolism and Cardiovascular Diseases - Category: Nutrition Source Type: research
Publication date: Available online 10 October 2020Source: Brain, Behavior, and ImmunityAuthor(s): Irene Esteban-Cornejo, Chelsea M. Stillman, Maria Rodriguez-Ayllon, Arthur F. Kramer, Charles H. Hillman, Andrés Catena, Kirk I. Erickson, Francisco B. Ortega
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research
Publication date: October 2020Source: Brain, Behavior, and Immunity, Volume 89Author(s): Xiaoqin Liu, Trine Munk-Olsen, Clara Albiñana, Bjarni J. Vilhjálmsson, Emil M. Pedersen, Vivi Schlünssen, Marie Bækvad-Hansen, Jonas Bybjerg-Grauholm, Merete Nordentoft, Anders D. Børglum, Thomas Werge, David M. Hougaard, Preben B. Mortensen, Esben Agerbo
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research
Publication date: Available online 10 October 2020Source: Molecular MetabolismAuthor(s): Holger Henneicke, Sarah Kim, Michael M. Swarbrick, Jingbao Li, Sylvia J. Gasparini, Joanne Thai, Daphne Foong, Lauryn L. Cavanagh, Colette Fong-Yee, Elisabeth Karsten, Ruby C.Y. Lin, Mark S. Cooper, Hong Zhou, Markus J. Seibel
Source: Molecular Metabolism - Category: Endocrinology Source Type: research
CONCLUSION: When gastroenterologists encounter NAFLD/NASH patients, serum CK should be verified. If hyperCKemia, frontal baldness, a hatched face, history of cataract surgery, and grip myotonia are noted, the possibility of MD may be considered. PMID: 33033573 [PubMed]
Source: World Journal of Hepatology - Category: Gastroenterology Tags: World J Hepatol Source Type: research
Authors: Tamai H, Shingaki N, Ida Y, Shimizu R, Maeshima S, Okamura J, Kawashima A, Nakao T, Hara T, Matsutani H, Nishikawa I, Higashi K Abstract BACKGROUND: Although clinical use of sofosbuvir plus ribavirin has been approved for patients infected with genotype 2 hepatitis C virus, patients ≥ 75-years-old have not been included in previous clinical trials. AIM: To evaluate the real-world safety and efficacy of sofosbuvir plus ribavirin for elderly patients (≥ 75-years-old) compared to nonelderly patients, we conducted a post-marketing prospective cohort study. METHODS: We treated 265 patients with ge...
Source: World Journal of Hepatology - Category: Gastroenterology Tags: World J Hepatol Source Type: research
Authors: Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Mendez-Sanchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M Abstract Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chr...
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
More News: Asthma | Brain | Cardiology | Cardiovascular | Centers for Disease Control and Prevention (CDC) | Children | Cough | Eating Disorders & Weight Management | H1N1 | H3N2 | Health | Heart | Hospitals | Infectious Diseases | Influenza | Influenza Vaccine | Intensive Care | International Medicine & Public Health | Laboratory Medicine | Neurology | Obesity | Oseltamivir | Pediatrics | Pneomococcal Vaccine | Pneumonia | Relenza | Respiratory Medicine | Sore Throat | Swine Flu (H1N1) Vaccine | Tamiflu | Vaccines | Zanamivir